iBio (IBIO) Income towards Parent Company (2010 - 2026)
iBio (IBIO) posted quarterly Income towards Parent Company of -$7.8 million for Q1 2026, down 58.63% year-over-year from -$19.0 million in Q1 2025, and up 13.68% quarter-over-quarter from -$9.1 million in Q4 2025.
iBio (IBIO) Income towards Parent Company (2010 - 2026) Analysis & Trends
iBio (IBIO) has reported Income towards Parent Company for 17 consecutive years, with -$7.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company fell 58.63% year-over-year to -$7.8 million; the TTM figure through Mar 2026 stood at -$27.5 million (down 53.49% YoY), while the FY2025 annual figure was -$81.6 million, down 761.76% from the prior year.
- Income towards Parent Company grew to -$7.8 million in Q1 2026 per IBIO's latest filing, from -$9.1 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$537000.0 in Q1 2024 and bottomed at -$23.0 million in Q4 2022.
- Historically, Income towards Parent Company has averaged -$5.8 million across 5 years, with a median of -$4.8 million in 2025.
- Annual changes were most pronounced in 2023 — Income towards Parent Company surged 93.66% — and 2025, when it tumbled 821.42%.
- iBio's Income towards Parent Company stood at -$23.0 million in 2022, then surged by 83.81% to -$3.7 million in 2023, then decreased by 19.47% to -$4.4 million in 2024, then tumbled by 104.43% to -$9.1 million in 2025, then gained by 13.68% to -$7.8 million in 2026.
- Business Quant data shows IBIO's Income towards Parent Company at -$7.8 million in Q1 2026, -$9.1 million in Q4 2025, and -$5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.85 Mn |
| Dec 31, 2025 | -9.09 Mn |
| Sep 30, 2025 | -5.72 Mn |
| Jun 30, 2025 | -4.84 Mn |
| Mar 31, 2025 | -4.95 Mn |
| Dec 31, 2024 | -4.45 Mn |
| Sep 30, 2024 | -3.99 Mn |
| Jun 30, 2024 | -4.53 Mn |
| Mar 31, 2024 | -537,000.00 |
| Dec 31, 2023 | -3.72 Mn |
| Sep 30, 2023 | -672,000.00 |
| Jun 30, 2023 | -1.10 Mn |
| Mar 31, 2023 | -1.02 Mn |
| Dec 31, 2022 | -22.99 Mn |
| Sep 30, 2022 | -10.59 Mn |
| Jun 30, 2022 | -6.67 Mn |
| Mar 31, 2022 | -5.64 Mn |
| Dec 31, 2021 | -4.73 Mn |
| Sep 30, 2021 | -3.75 Mn |
| Jun 30, 2021 | -10.09 Mn |